Risk of multiple sclerosis in patients with psoriasis receiving anti-IL-17 agents: A case-based review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38345289/
Biologics approved for psoriasis exhibit favorable safety profiles, and serious adverse events have rarely been reported. In this report, we present the case of a patient treated with ixekizumab, an...
This case report discusses a patient developing multiple sclerosis after ixekizumab treatment for psoriasis. While rare, possible inflammatory events in the central nervous system with anti-IL-17 agents warrant consideration.
Modulating the Gut Microbiome in Multiple Sclerosis Management: A Systematic Review of Current Interventions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38137679/
This review attempted to explore all recent clinical studies that have investigated the clinical and autoimmune impact of gut microbiota interventions in multiple sclerosis (MS), including dietary protocols, probiotics, fecal...
Recent studies highlight the positive impact of gut microbiota interventions (diet, probiotics, FMT, IF) on multiple sclerosis, improving relapse rates, disability scores, fatigue, inflammation, mood, and quality of life.
Tumor or Demyelination? Three Tumefactive Multiple Sclerosis Case Reports and Literature Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38641243/
TMS is difficult to differentiate from brain tumors. It is necessary to improve the understanding of these diseases, to apply the correct diagnosis and treatment and to avoid unnecessary invasive...
Tumefactive multiple sclerosis (TMS) can mimic brain tumors with large lesions. Early diagnosis, understanding, and proper treatment are crucial to avoid unnecessary surgery and ensure accurate management.
Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39254048/
The number of people with PMS with relapses is probably slightly reduced with rituximab at two years, and interferon beta-1b at three years, compared to placebo. Both drugs are also...
This network meta-analysis evaluated 23 studies on treatments for progressive multiple sclerosis, finding limited evidence on efficacy and safety, with rituximab and interferon beta-1b showing slight relapse reduction compared to placebo.
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38648580/
Although sNfL correlated with the presence of Gd+ lesions, most participants with Gd+ lesions did not have elevations in sNfL levels. These observations have implications for the use and interpretation...
In the RESTORE trial, serum neurofilament light chain (sNfL) levels correlated with gadolinium-enhancing lesions in MS, but most patients with lesions showed no significant sNfL elevation, complicating its use as a biomarker.